Comparison of the efficacy and safety of intralesional injection of tranexamic acid and Platelet Rich Plasma in the treatment of macular amyloidosis

Comparison of the effectiveness of topical fusidic acid and mometasone on complications after fractional CO2 laser therapy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250630066301N1

Enrollment

Registered

2025-08-01

Start date

2025-06-17

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Post-inflammatory hyperpigmentation (PIH. Condition 2: Hypertrophic scar. Condition 3: Erythema. Condition 4: Infection of the scar site. Postinflammatory hyperpigmentation Hypertrophic scar Other erythematous conditions Local infection of the skin and subcutaneous tissue, unspecified

Interventions

Intervention 1: Intervention group: All participants will first undergo fractional CO2 laser treatment in two passes with standard settings (density 1.1, energy 80 mJ in the first pass

density 0.9, energy 60 mJ in the second pass). The procedure will be performed with standard safety precautions and without cooling. After fractional CO2 laser treatment, 0.1% mometasone furoate oint

density 0.9, energy 60 mJ in the second pass). The procedure will be performed with standard safety precautions and without cooling. After laser treatment, 2% fusidic acid cream will be applied to the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients should be older than 18 years old. Patient should have acne scars on the face.

Exclusion criteria

Exclusion criteria: Patients have a history of sensitivity to fusidic acid or Mometazon components. Patients have an active infection at the scar site. Patients are pregnant or breastfeeding. Patients are undergoing hormone therapy or concomitant use of contraceptives. Patients have used topical treatments containing corticosteroids, peels, or lighteners in the study areas within the past 3 months.

Design outcomes

Primary

Measure	Time frame
Patients' improvement score. Timepoint: At baseline (month 0), and at 1, 2, and 3 months after intervention initiation. Method of measurement: using a 5-point patient rating scale.;Physician's recovery score. Timepoint: At baseline (month 0), and at 1, 2, and 3 months after intervention initiation. Method of measurement: using a 5-point physician rating scale.;Infection at the treatment site. Timepoint: At baseline (month 0), and at 1, 2, and 3 months after intervention initiation. Method of measurement: Clinical evaluation by a dermatologist based on the presence of signs of infection including: purulent discharge, diffuse erythema, persistent pain, local or generalized fever, and the need for drug treatment (antibiotics).;Dermoscopic score of the lesion. Timepoint: At baseline (month 0), and at 1, 2, and 3 months after intervention initiation. Method of measurement: Clinical evaluation and scoring by a dermatologist using dermoscopic criteria on a five-point rating scale.;Severity of post-inflammatory hyperpigmentation (PIH) from the physician’s perspective. Timepoint: At baseline (month 0), and at 1, 2, and 3 months after intervention initiation. Method of measurement: ????? ?????? ?????? (Visual Analogue Scale) ???? ?? ?? ?? ?????????? ?? ???? ??? ????? ????? ?? ?? ??? (???? ?????) ?? ?? (??????? ??? ???? ?????) ?????? ? ??????????? ??????.	—

Measure

Time frame

Patients' improvement score. Timepoint: At baseline (month 0), and at 1, 2, and 3 months after intervention initiation. Method of measurement: using a 5-point patient rating scale.;Physician's recovery score. Timepoint: At baseline (month 0), and at 1, 2, and 3 months after intervention initiation. Method of measurement: using a 5-point physician rating scale.;Infection at the treatment site. Timepoint: At baseline (month 0), and at 1, 2, and 3 months after intervention initiation. Method of measurement: Clinical evaluation by a dermatologist based on the presence of signs of infection including: purulent discharge, diffuse erythema, persistent pain, local or generalized fever, and the need for drug treatment (antibiotics).;Dermoscopic score of the lesion. Timepoint: At baseline (month 0), and at 1, 2, and 3 months after intervention initiation. Method of measurement: Clinical evaluation and scoring by a dermatologist using dermoscopic criteria on a five-point rating scale.;Severity of post-inflammatory hyperpigmentation (PIH) from the physician’s perspective. Timepoint: At baseline (month 0), and at 1, 2, and 3 months after intervention initiation. Method of measurement: ????? ?????? ?????? (Visual Analogue Scale) ???? ?? ?? ?? ?????????? ?? ???? ??? ????? ????? ?? ?? ??? (???? ?????) ?? ?? (??????? ??? ???? ?????) ?????? ? ??????????? ??????.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKiana Rahmati

Mashhad University of Medical Sciences

Kianarahmati222@gmail.com+98 51 3800 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026